AstraZeneca subsidiary MedImmune Inc opened a new biologics research and development centre in Cambridge, UK, a major expansion to its base at the former Cambridge Antibody Technology facility.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.